

FROM ALGORITHMS TO MEDICINES: THE EMERGING ROLE OF AI IN DRUG DESIGN AND DEVELOPMENT

Riddhi Gandhi^{*1}, Anjali Patel¹, Hemani Mistry¹, Sakshi Gandhi¹, Satyajit Sahoo², Dhananjay
B. Meshram³

¹Student, Pioneer Pharmacy College, Ajwa-Nimeta Road, Vadodara, Gujarat, India -390019.

²Associate Professor, Pioneer Pharmacy College, Ajwa-Nimeta Road, Vadodara, Gujarat, India -390019.

³Principal, Pioneer Pharmacy College, Ajwa-Nimeta Road, Vadodara, Gujarat, India -390019.

Article Received: 14 August 2026 | Article Revised: 04 September 2026 | Article Accepted: 24 September 2026

***Corresponding Author: Riddhi Gandhi**

Student, Pioneer Pharmacy College, Ajwa-Nimeta Road, Vadodara, Gujarat, India -390019.

DOI:

How to cite this Article: Riddhi Gandhi, Anjali Patel, Hemani Mistry, Sakshi Gandhi, Satyajit Sahoo, Dhananjay B. Meshram (2026) FROM ALGORITHMS TO MEDICINES: THE EMERGING ROLE OF AI IN DRUG DESIGN AND DEVELOPMENT. World Journal of Pharmaceutical Science and Research, 5(10), 222-233.



Copyright © 2026 Riddhi Gandhi | World Journal of Pharmaceutical Science and Research.

This work is licensed under creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0).

ABSTRACT

Traditional drug discovery process has several steps: Identification and validation of targets; identification of hits; lead optimization; preclinical research; clinical trials; regulatory approval. Recent breakthroughs in Artificial Intelligence are revolutionizing this process, by allowing the fast analysis of complex biological, chemical and clinical data. Target identification, virtual screening, de novo molecular design, lead optimization, drug repurposing, prediction of absorption, distribution, metabolism, excretion and toxicity, virtual clinical trial optimization, etc. are among the applications of AI. New technologies like AlphaFold, for example, have taken protein structure prediction forward, aiding target characterization and structure-based drug design. The infiltration of AI into the field of drug development is shown by platforms such as DeepChem, Atomwise, *Insilico* Medicine and Schrödinger. An example of how AI has positively impacted has been in the wait for drug repurposing and therapeutic development during the COVID-19 pandemic. The future holds promise for additional changes in the landscape of drug discovery, with generative AI, personalized medicine, multi-omics integration, and autonomous experimentation poised to contribute to these transformations. Therefore, it is important to think of AI as a tool to assist in the decision-making process and to strive to make safer and more effective therapeutics.

KEYWORDS: generative AI, virtual screening, drug design, target identification and validation, lead optimization.

1. INTRODUCTION

Artificial Intelligence (AI) is an area of computer science that allow computers to be used to carry out tasks that normally would require human intelligence such as the ability to learn from data, recognize patterns in data, predict future occurrences, solve problems or make decisions. AI systems can handle massive amounts of data and detect intricate relationships, which could be hard to see through with traditional analysis methods. AI has been increasingly embraced by the pharmaceutical industry due to the vast amounts of data in the field of drug discovery, including chemical, biological, genomic, structural and clinical data. The pharmaceutical industry may use conventional drug discovery approaches, which are resource intensive, time-consuming and cost-consuming and may cause failure. To enhance this process, AI can be applied to analyze vast amounts of data to identify valuable insights and forecast the properties and activities of drug candidates and possible adverse side effects before they even enter the laboratory.^[1,2]

Drug design is the rational design or modification of molecules so that they interact with particular biological targets and elicit a desired response. There have been already some traditional computational methods that have helped the rational drug design, such as: Structure–Activity Relationship (SAR) and Quantitative Structure–Activity Relationship (QSAR), molecular docking, molecular dynamics and quantum chemical calculations. AI extends these approaches by being able to learn the intricate connections between molecular structures, biological targets and pharmacological outcomes. The process of drug development is a step by step process which converts a potential drug into a safe and effective drug for human use. The drug-development pathway involves identification of a disease-associated biological target and its subsequent validation, hit identification, optimization of hits, preclinical trials and clinical trials for potential regulatory approval. Throughout each step, AI has the potential to enhance the process, such as by focusing activities on candidate molecules with the greatest potential for success, predicting biological and physicochemical properties, and spotting possible safety challenges and aiding in decision-making.^[3,4]

AI is becoming an integral part of modern-day pharmaceutical research. The use of AI is a revolution in the pharmaceutical research as it has revolutionized scientific research by improving the efficiency, speed and accuracy of it. It undertakes tasks to analyze large and complex datasets, which then uncovers relationships between components that may not be otherwise evident or easily-observed using more traditional data analysis methods. This has opened new possibilities for AI to be an essential tool in the drug development process. It also assists scientists in pinpointing new drug targets and forecasting compound activity and molecule structure prior to entering the laboratories. AI can also aid in drug repurposing, finding new connections between existing drugs and diseases that were not previously known.^[5,6]

2. TRADITIONAL DRUG DISCOVERY PROCESS

Traditional drug discovery process is associated with a sequential pathway starting from the identification and validation of a disease-related target, followed by hit discovery, lead optimization, preclinical testing, clinical trials and regulatory approval.^[7]



Figure 1: Traditional Drug Discovery Process.

2.1 Target Identification and Target Validation

Target identification is the selection of a biological molecule linked to stage of disease development or progression. The targets may include enzymes, receptors, genes or any other biomolecules. Typically, potential targets are identified by genomic studies, gene-expression analysis, biochemical pathways, and gene serology.^[8] Once the target has been identified, it is engaged in target validation in which it establishes whether the modulation of the selected target can yield a therapeutic effect. A validated target should show a definable link to the disease biology and the target should be easily druggable to enable therapeutic intervention.^[9]

2.2 Hit Identification

Hit identification is the process involving search for compounds which are capable of producing measurable activity against the validated target. Large chemical libraries can be assessed using high throughput screening and a variety of other strategies can be implemented including natural product screening, virtual screening and fragment-based screening. Once hits are confirmed, they are rigorously tested for potency, selectivity, reproducibility and preliminary safety to advance them for optimization.^[10]

2.3 Lead Optimization

For optimizing the promising hit or lead, several iterative changes are applied to the structure to enhance potency, selectivity, pharmacokinetics and safety, all while maintaining the biological activity. These properties include solubility, stability, permeability, metabolic stability, formulation compatibility and synthetic feasibility. The purpose is to obtain a candidate with a reasonable balance of appropriate structure for preclinical evaluation.^[11]

2.4 Preclinical Studies

Pharmacological and toxicological examination of the drug candidate occurs in preclinical studies before the drug is administered to humans. In vitro studies using biochemical systems and cell culture are succeeded by in vivo studies that employ suitable animal models. Some of the important parameters are the absorption, distribution, metabolism and

excretion (ADME), pharmacological activity, toxicity, pharmacokinetics and suitable dose range. Candidates showing acceptable safety and efficacy profiles may proceed towards its clinical trials.^[12]

2.5 Clinical Trials

Clinical trials assess the safety, efficacy and therapeutic value of the investigational drug in humans.

Phase 0: Exploratory microdosing studies may provide preliminary pharmacokinetic information.

Phase I: Primarily determines safety, tolerability and pharmacokinetics.

Phase II: Investigates therapeutic efficacy, dose selection and additional safety parameters in patients.

Phase III: Large-scale studies confirm efficacy and safety and compare the candidate drug with existing treatments.

Phase IV: Post-marketing surveillance evaluates long-term effectiveness and detects uncommon or delayed adverse effects.^[13]

2.6 Regulatory Approval

Followed by successful clinical development, a comprehensive regulatory submission containing evidence of quality, safety and efficacy is evaluated by the appropriate regulatory authority. The evaluation will cover Clinical, Preclinical, pharmaceutical development, Chemistry and Manufacturing and Controls (CMC) and labeling and Risk–Benefit. Once given approval, ongoing pharmacovigilance is required to check the effectiveness and safety of the drug in the larger population. There are many Pharmacovigilance systems to keep a check on rare or late adverse effects of the drugs: Pharmacovigilance Programme of India (PvPI), World Health Organization (WHO), U.S. Food and Drug Administration (USFDA).^[14]

2.7 Challenges

Although conventional methods have successfully produced numerous therapeutic agents, the process has several major limitations, which include:

- Long development timelines (10-15 years)
- High research and development costs
- High candidate attrition
- Limited efficiency of screening extremely large chemical libraries
- Late-stage toxicity and pharmacokinetic failures.^[15]

3. APPLICATIONS OF AI IN DRUG DISCOVERY

AI is being introduced at various phase points of drug discovery and development. Machine learning, deep learning and generative AI can be used to analyze vast amounts of data on chemical, biological and clinical activity to identify therapeutic targets, predict the activity of drugs, design new molecules, optimize lead compounds and assess their safety.^[16]

3.1 Target identification and validation

AI can integrate genomic, transcriptomic, proteomic and clinical information to pinpoint genes, proteins and biological pathways that are linked to disease. Machine Learning can identify patterns to detect disease, identify possible biomarkers, study Protein–Protein Interaction Networks, etc. This allows the selection of a group of candidate targets which can in turn be ranked according to the biological relevance, druggability and therapeutic usefulness and predicted safety. In this way, AI can aid in more rapid and data-driven identification and validation of targets.^[17]

3.2 Virtual Screening and Hit Identification

Virtual Screening using AI can be used to evaluate vast chemical libraries to find compounds that are likely to interact with a chosen biological target. Use of machine learning models to predict binding affinity and activity via molecular descriptors and fingerprints, as well as using protein structure and past activity data. This will enable researchers to shortlist and opt for compounds that are more likely to be successful for further testing in the laboratory and more effectively identify hits.^[18]

3.3 De Novo Drug Design

In contrast to existing molecular structures used by AI, generative AI can design new ones. Variational Auto-encoders, Generative Adversarial Networks, Transformers and Diffusion Models can be used to generate molecules with specific properties including drug-likeness. This strategy opens up the possibility to discover new drugs that will have additional chemical space to explore and greatly decrease reliance on traditional trial and error molecular design.^[19]

Another application is optimization of molecular structures and designing molecules based on their structures. AI can help in the optimization of lead compounds, making predictions about the effect of structural changes on metabolic stability and toxicity. AI can be used in structure-based drug design to analyze the structure of a protein, such as determining binding sites and predicting how a drug will interact with a target. These tools enable the design of molecules with greater binding and therapeutic properties, while minimizing the amount of time spent in synthesis and testing.^[20]

3.5 Drug Repurposing

AI helps identify novel therapeutic applications for existing drugs by combining various data sources, including drug–target relationships, disease pathways, gene-expression information, clinical data and scientific literature. Repurposing of drugs by AI could shorten the time and costs to develop a safety and pharmacokinetic profile, as it may build upon existing knowledge available for other drugs that have been repurposed. This method is especially helpful in the case of rare diseases and emerging infectious diseases.^[21]

3.6 ADMET Prediction

Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) properties can be predicted early in the drug discovery process by AI. The oral bioavailability, permeable, tissue distribution, metabolic stability, and elimination property can be estimated using machine learning models. AI can help predict other toxicities, like hepatotoxicity, cardiotoxicity, nephrotoxicity, genotoxicity and carcinogenicity. The early stages of screening candidates make use of the knowledge of their undesirable ADMET characteristics to eliminate unacceptable candidates and prevent failures during late stages of drug development.^[22]

3.7 Clinical Trial Optimization

AI can enhance clinical trial efficiency by helping to identify patients for trial, stratify patients, design trials, optimize doses and monitoring patient safety. Using the stored information in the Electronic Health Records, clinical histories and genomic information can find participants appropriate for the study. AI can also identify any potential adverse events, protocol deviations and patient dropouts during trials and enhance the quality of trials and shorten delays.^[23]

4. AI TOOLS AND PLATFORMS

Several AI platforms demonstrate the growing integration of computational intelligence into pharmaceutical research.

Alpha Fold

Alpha Fold is a protein structure prediction AI system. It is created by Google Deep Mind. Three-dimensional structures of proteins from their amino acid sequences can be predicted using deep learning. For a prolonged duration, structures of proteins were given by techniques such as X-ray crystallography, NMR spectroscopy and Cryo-electron microscopy. By providing predicted structures for a very large number of proteins, Alpha Fold has expanded access to structural information. These structures can support identification of binding sites, molecular docking, virtual screening and structure-based drug design.^[24]

DeepChem

DeepChem is an open source platform for leveraging machine learning and deep learning capabilities across computational chemistry and drug discovery. Supports molecular representation including fingerprints, graph based representations. Applications include QSAR modelling, molecular property prediction, virtual screening, ADMET prediction, toxicity assessment and molecular generation.^[25]

Atomwise

Atomwise has built AtomNet® – a deep-learning based drug discovery platform for structure-based drug discovery. The method employs three dimensional protein structures and information about chemical compounds to help identify and rank molecules for further investigation, based on their potential interactions.^[26]

Insilico Medicine

Insilico Medicine applies AI throughout the drug discovery process. Its examples of Pharma.AI ecosystem platforms are PandaOmics for target discovery, Chemistry42 molecular design, inClinico for clinical-trial prediction. The platform is the new wave of an integrated end-to-end AI drug discovery process.^[27]

Schrödinger

Schrödinger's product line integrates molecular modelling, simulation, computational chemistry and machine learning. The computational methods can be utilized for molecular docking, molecular dynamics, quantum mechanical calculations, structure-based drug design and lead optimization.^[28]

Table 1: AI Tools and Platforms.

AI Tool / Platform	Developer	Primary Function	Major Applications in Drug Discovery
AlphaFold	Google DeepMind	Protein structure prediction	Structure-based drug design, target identification, binding site prediction, protein structure analysis
DeepChem	DeepChem Community (Open Source)	AI framework for computational chemistry	QSAR modeling, virtual screening, molecular property prediction, ADMET and toxicity prediction
Atomwise (AtomNet®)	Atomwise Inc.	AI-powered virtual screening	Hit identification, binding affinity prediction, lead optimization
Insilico Medicine (Pharma.AI)	Insilico Medicine	End-to-end AI drug discovery platform	Target identification, de novo drug design, lead optimization, clinical trial prediction
Benevolent AI	BenevolentAI	Knowledge graph-based drug	Target discovery, drug repurposing, disease pathway analysis

		discovery	
Schrödinger	Schrödinger Inc.	Molecular modeling and computational chemistry	Molecular docking, molecular dynamics, structure-based drug design, lead optimization

5. ADVANTAGES OF AI IN DRUG DISCOVERY AND DEVELOPMENT

The advantages of AI on drug design and development are:

➤ Acceleration of Drug Discovery

AI can quickly digest vast chemical and biological data sets and identify potential targets and molecules. The use of virtual screening and generative molecular design can save time in the early discovery stages.

➤ Cost minimization

AI speeds up screening by pinpointing high potential leads and eliminates non-viable compounds before costly laboratory trials begin.

➤ Multi-objective optimization

AI models can take into account several features at once, including potency, selectivity, ADMET properties, and toxicity, aiding in more informed candidate selection.

➤ Support in the field of Precision Medicine

Combining genomic, proteomic and clinical information can guide the identification of biomarkers and patient subpopulations more likely to be predictive of response to a particular therapy.

➤ Rapid Response to Emerging Diseases

AI can rapidly examine pathogen genomes and pinpoint possible targets and test current drugs to see if they might be repurposed. This was especially relevant during the COVID-19 pandemic. The biggest benefit of AI is not just that it is fast but it is also able to link masses of data and then transform it into actionable predictions.^[29]




Figure 2: Advantages of AI in Drug Design and Development.

6. CHALLENGES AND LIMITATIONS

Despite its several advantages, AI-driven drug discovery faces some challenges and limitations in data quality, biological complexity, and regulatory pathways.

➤ Data Quality and Algorithmic Bias

The quality of training data is important for the proper effectiveness of AI models. Pharmaceutical datasets may go missing, inaccurate, industry-specific or only available for specific types of diseases and populations. Unreliable predictions can subsequently result into poor quality of data.

➤ Lack of Explainability

The reason behind a specific prediction is not always clear for many deep-learning models, making them a “black box”. If it is not interpretable, it may be difficult to establish scientific confidence and to evaluate it for regulatory purposes.

➤ Need for Experimental Validation

The computational prediction does not necessarily describe what the case in biology is. Biochemical, cellular, preclinical and eventually clinical validation is necessary for AI molecules and predictions.

➤ Biological Complexity

Biological diseases are known to be very complex and may involve multiple genes, proteins, pathways, environmental factors and patient-specific characteristics. It is possible that this complexity cannot be fully captured by AI models^[30].

7. REAL-WORLD EXAMPLES

7.1 AI-Assisted Drug Discovery during COVID-19

AI could be a pivotal solution for tackling new outbreaks of infectious diseases, like the COVID-19 pandemic. After the release of the SARS-CoV-2 genome, the computational tools were used for the study of the viral proteins, potential therapeutic targets and existing drugs.^[31]

One such drug currently approved for the treatment of rheumatoid arthritis is baricitinib. Its potential relevance for COVID-19 was identified using the AI-assisted analysis, which discovered possible related effects in the areas of viral entry and inflammatory signaling. Further clinical trials confirmed its use in appropriate hospitalized patients. The example highlighted the ability of AI to cut through the innovation curve by integrating target analysis, drug repurposing and clinical evidence for therapeutic decision making in a health emergency.^[32]

8.2 AI designated kinase inhibitors by *Insilico Medicine*

The example of *Insilico Medicine* is an excellent example of the use of AI in different phases of drug discovery. The company applied its AI-based target identification and molecular design solutions to discover INS018_055, a small molecule inhibitor of the TNIK in PF. The candidate's journey from computational support to clinical development demonstrates the potential of AI-generated hypotheses and molecules to transition from computational to experimental and clinical assessment. Indeed, the case reports here highlights how AI can enable integrated target discovery, molecular generation, optimization, preclinical evaluation and clinical development in one workflow.^[33]

8.3 Alpha Fold and Protein Structure Prediction

Alpha Fold is also a significant example of the impact AI can have in the pharmaceutical industry in the real world. The knowledge of protein structure is of great importance in understanding the biological function and in designing

molecules which bind to particular target proteins.^[34]

Alpha Fold can predict the structure of proteins quickly and confidently, opening up new vistas for structural information for researchers and enabling a range of downstream applications, such as binding-site analysis, molecular docking, virtual screening and structure-based drug design.^[35]

Experimental structural and biological validation, however, is still needed, especially in cases where there is conformational change due to the protein or too binding with the ligand, and/or structural flexibility.^[36]

8. FUTURE TRENDS

8.1 Generative AI for Molecular Design

The use of generative AI is anticipated to play a greater role in drug design as it will explore pockets of chemical space that do not exist from known drugs. Modern models can now be used to produce molecular structures that optimize multiple properties at once such as drug-likeness, biological activity, and synthetic accessibility and ADMET properties. REINVENT, a publicly available computer software program helps to generate new drug molecules. The molecules identified as 'reinforces' in REINVENT have particular desirable characteristics like better target affinity or desired pharmacokinetic properties.^[37]

Other strategies, such as transformer-based models and diffusion models, also hold promise for enhancing the capacity of AI models to create novel molecules with therapeutic potential or chemists, thereby advancing the field's potential for innovation. The trajectory of the future is now changing from:

Search for most suitable molecule among the existing molecules toward Design a new molecule that has the desired properties.^[38]

8.2 AI in Personalized Medicine

Another big application in the future is personalized medicine. AI can integrate genomic, proteomic, metabolomics and clinical information to develop more comprehensive patient profiles.^[39]

More precise machine learning or deep learning methods will be likely to lead to the improved identification of novel biomarkers and therapeutic targets, allowing for proper diagnosis and treatment planning. Simple predictive models based on the power of AI will be able to predict disease progression, the onset of treatment resistance, and can optimize the dosage of a drug with a minimum dosage, thus minimizing side effects. The ability to provide a wearable device and continuous health-monitoring systems may also enable the provision of real-time patient information, facilitating the implementation of treatment protocols as necessary in response to evolving clinical circumstances. Several hurdles remain that must be overcome to allow AI to play a more fully realized role in personalized medicine, such as data privacy issues, how transparent the algorithms are, regulatory responsibility, and access to AI tools.^[40, 41]

8.3 Autonomous and Drug discovery with AI

One of the new concepts is the use of automated laboratory systems coupled with AI. In these processes, AI might suggest an experiment, automate it, and receive experimental data back to the AI model to determine the next experiment to observe based on the new data. This establishes a potential trickle down scenario:

Model improvement → automated experiment → experimental data → next experiment → AI prediction

Such systems may significantly speed up the iterative drug discovery process.^[42]

10. CONCLUSION

AI is revolutionizing the pharmaceutical industry by bringing data-driven strategies to various phases of drug discovery and development. AI can boost the efficiency, speed and accuracy of pharmaceutical research, from target identification and virtual screening to de novo molecular design, lead optimization, ADMET prediction, and drug repurposing and clinical trial optimization with tools like Alpha Fold, AI has proven its ability to solve some of the fundamental questions in structural biology, and AI companies like DeepChem, Atomwise, BenevolentAI and Schrödinger are examples of the many different approaches being used for drug discovery.

Artificial Intelligence has its major benefit in its capability to analyze and dissect huge and complicated data sets, and uncover connections that might not have been identified and prioritize scientific theories that are likely of the greatest value. AI can help minimize late-stage failure and optimize resource allocation by predicting activity and toxicity early on. However, AI should not be considered as a substitute for any medicinal chemist, pharmacologist, biologist, clinician or experimental research. Predictions need extensive experimental and clinical testing, and problems of data quality, explainability, and biological complexity, regulatory and ethical considerations need to be overcome.

The future of pharmaceutical research isn't going to be about AI versus humans, it's going to be about AI and humans and experiments. As generative AI, multi-omics analysis, personalized medicine and protein structure prediction and automated experimentation continues to be integrated across the drug discovery landscape, it could potentially become more interconnected and adaptive. AIRDD could transform the way drugs are discovered from a more trial-and-error to a more scientific, rational and efficient process, and could bring us closer to the ideal of discovering safer, more effective and more personalized medicines, with responsible use and appropriate validation.

11. REFERENCES

1. Soori M, Arezoo B, Dastres R. Artificial intelligence, machine learning and deep learning in advanced robotics, a review. *Cogn Robot*, 2023; 3: 54-70.
2. Paul D, Sanap G, Shenoy S, Kalyane D, et al. Artificial intelligence in drug discovery and development. *Drug Discov Today*, 2021; 26(1): 80-93.
3. Salve M, Pawar R, Bundhe S, Suroshe P, et al. A comprehensive review on drug design: Principles, approaches, and recent advances. *Int J Pharm Sci*, 2026; 4: 339-358.
4. Biala G, Kedzierska E, Kruk-Slomka M, Orzelska-Gorka J, et al. Research in the field of drug design and development. *Pharmaceuticals*, 2023; 16(9): 1283.
5. Huanbutta K, Burapapadh K, Kraisit P, Sriamornsak P, et al. Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. *Eur J Pharm Sci*, 2024; 203: 106938.
6. Fahim YA, Hasani IW, Kabba S, Ragab WM. Artificial intelligence in healthcare and medicine: Clinical applications, therapeutic advances, and future perspectives. *Eur J Med Res*, 2025; 30(1): 848.
7. Al Qaraghuli MM, Alzahrani AR, Niwasabutra K, Obeid MA, et al. Where traditional drug discovery meets modern technology in the quest for new drugs. *Ann Pharmacol Pharm*, 2017; 2(6): 1061.
8. Paananen J, Fortino V. An omics perspective on drug target discovery platforms. *Brief Bioinform*, 2020; 21(6): 1937-1953.

9. Singh SK, Yadav P, Mishra P, Shameem A, et al. Drug discovery. *Int J Creat Res Thoughts*, 2021; 9: 1829-1831.
10. Szymański P, Markowicz M, Mikiciuk-Olasik E. Adaptation of high-throughput screening in drug discovery-toxicological screening tests. *Int J Mol Sci*, 2012; 13(1): 427-452.
11. Gupta S, Kesarla R, Omri A. Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. *ISRN Pharm*, 2013; 2013: 848043.
12. Tejas D, Monika B, Anuksha S, Ganesh R. Review on preclinical and clinical studies. *Int J Creat Res Thoughts*, 2023; 11(3): 31-39.
13. Rohilla A, Singh RK, Sharma D, Keshari R, et al. Phases of clinical trials: A review. *Int J Pharm Chem Biol Sci*, 2013; 3(3): 700-703.
14. Suvarna V. Phase IV of drug development. *Perspect Clin Res*, 2010; 1(2): 57-60.
15. Hua Y, Dai X, Xu Y, Xing G, et al. Drug repositioning: Progress and challenges in drug discovery for various diseases. *Eur J Med Chem*, 2022; 234: 114239.
16. Preet S DJ, Ankita T, Deepak Y. AI-driven innovations in pharmaceuticals: Optimizing drug discovery and industry operations. *RSC Pharm*, 2025; 2(3): 437-454.
17. Altucci L, Badimon L, Balligand JL, Baumbach J, et al. Artificial intelligence and network medicine: Path to precision medicine. *N Engl J Med*, 2025; 9.
18. Raschka S, Kaufman B. Machine learning and AI-based approaches for bioactive ligand discovery and GPCR-ligand recognition. *Methods*, 2020; 180: 89-110.
19. Mouchlis VD, Afantitis A, Serra A, Fratello M. Advances in de novo drug design: From conventional to machine learning methods. *Int J Mol Sci*, 2021; 22(4): 1676.
20. Wang Q, Sun B, Yi Y, Velkov T. Progress of AI-driven drug-target interaction prediction and lead optimization. *Int J Mol Sci*, 2025; 26(20): 10037.
21. Wan Z, Sun X, Li Y, Chu T. Applications of artificial intelligence in drug repurposing. *Adv Sci*, 2025; 12(14): e2411325.
22. Jung W, et al. Absorption distribution metabolism excretion and toxicity property prediction utilizing a pre-trained natural language processing model and its applications in early-stage drug development. *Pharmaceuticals*, 2024; 17(3): 382.
23. Fahim YA, Hasani IW, et al. Artificial intelligence in healthcare and medicine: Clinical applications, therapeutic advances, and future perspectives. *Eur J Med Res*, 2025; 30(1): 848.
24. Nussinov R, Zhang M, Liu Y, Jang H. AlphaFold, artificial intelligence (AI), and allostery. *J Phys Chem B.*, 2022; 126(34): 6372-6383.
25. Pathan I, Raza A, Sahu A, Joshi M, et al. Revolutionizing pharmacology: AI-powered approaches in molecular modeling and ADMET prediction. *Med Drug Discov*, 2025; 28: 100223.
26. Jarallah SJ, Almughem FA, Alhumaid NK, Al Fayeze N, et al. Artificial intelligence revolution in drug discovery: A paradigm shift in pharmaceutical innovation. *Int J Pharm*, 2025; 680: 125789.
27. Kamya P, Ozerov IV, Pun FW, et al. PandaOmics: An AI-driven platform for therapeutic target and biomarker discovery. *J Chem Inf Model*, 2024; 64(10): 3961-3969.
28. Pavithra P, Sidharth M, Velvizhi S, Yogapriya C, et al. Computational strategies in rational drug design: A software-centric review. *Int J Pharm D Sci*, 2026; 5(4): 3945-3962.

29. Rehman AU, Li M, Wu, et al. Role of artificial intelligence in revolutionizing drug discovery. *Fundam Res*, 2024; 5(3): 1273-1287.
30. Ferreira FJN, Carneiro AS. AI-driven drug discovery: A comprehensive review. *ACS Omega*, 2025; 10(23): 23889-23903.
31. Kaushik AC, Raj U. AI-driven drug discovery: A boon against COVID-19? *AI Open*. 2020; 1:1-4.
32. Richardson PJ, Robinson BWS, Smith DP, Stebbing J. The AI-assisted identification and clinical efficacy of baricitinib in the treatment of COVID-19. *Vaccines*, 2022; 10(6): 951.
33. Ren F, Aliper A, Chen J, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. *Nat Biotechnol*, 2025; 43: 63-75.
34. Schmidt T, Bergner A, Schwede T. Modelling three-dimensional protein structures for applications in drug design. *Drug Discov Today*, 2014; 19(7): 890-897.
35. Uzoeto HO, Cosmas S, Bakare TT, et al. AlphaFold-latest: Revolutionizing protein structure prediction for comprehensive biomolecular insights and therapeutic advancements. *Beni-Suef Univ J Basic Appl Sci*, 2024; 13: 46.
36. Zhang B, Zhu J, Chen HF, Liu LN. AlphaFold-based peptide structure prediction: Opportunities, limitations, and future directions. *Biotechnol Adv*, 2026; 92: 108977.
37. Loeffler HH, He J, Tibo A, et al. REINVENT 4: Modern AI-driven generative molecule design. *J Cheminform*, 2024; 16: 1-16.
38. Khater T, Alkhatib SA, AlShehhi A, et al. Generative artificial intelligence based models optimization towards molecule design enhancement. *J Cheminform*, 2025; 17(1): 116.
39. Bajwa J, Munir U, Nori A, Williams B. Artificial intelligence in healthcare: Transforming the practice of medicine. *Future Healthc J.*, 2021; 8(2): e188-e194.
40. Alum EU. AI-driven biomarker discovery: Enhancing precision in cancer diagnosis and prognosis. *Discov Oncol*, 2025; 16(1): 313.
41. Perlekar P, Desai A. The role of artificial intelligence in personalized medicine: Challenges and opportunities. *Metall Mater Eng*, 2025; 31: 85-92.
42. da Silva RGL. The advancement of artificial intelligence in biomedical research and health innovation: Challenges and opportunities in emerging economies. *Glob Health*, 2024; 20(1): 44.